Table 1.
Demographics of subjects aged 60–80 and cognitively normal at the time of amyloid PET imaging
| Characteristic | ADNI (n = 229) | A4 (n = 2294) | AIBL(n = 515) | Insight 46 (n = 415) | HABS (n = 128) |
|---|---|---|---|---|---|
| APOE*4 status, n (%) | (n = 229) | (n = 2294) | (n = 515) | (n = 415) | (n = 128) |
| APOE*4+ | 72 (31.4%) | 876 (38.2%) | 144 (28.0%) | 117 (28.2%) | 43 (33.6%) |
| APOE*4− | 157 (68.6%) | 1418 (61.8%) | 371 (72.0%) | 298 (71.8%) | 85 (66.4%) |
| APOE genotype, n (%) | (n = 229) | (n = 2294) | (n = 515) | (n = 403)a | (n = 128) |
| 2/2 | 0 (0%) | 9 (0.4%) | 2 (0.4%) | 0 (0%) | 2 (1.6%) |
| 2/3 | 29 (12.7%) | 210 (9.2%) | 70 (13.6%) | 53 (13.1%) | 5 (3.9%) |
| 2/4 | 5 (2.2%) | 63 (2.7%) | 10 (1.9%) | 7 (1.7%) | 5 (3.9%) |
| 3/3 | 128 (55.9%) | 1199 (52.3%) | 299 (58.1%) | 233 (57.8%) | 77 (60.2%) |
| 3/4 | 64 (27.9%) | 732 (31.9%) | 116 (22.5%) | 100 (24.8%) | 36 (28.1%) |
| 4/4 | 3 (1.3%) | 81 (3.5%) | 18 (3.5%) | 10 (2.5%) | 2 (1.6%) |
| Age (y), mean (SD) | (n = 229) | (n = 2294) | (n = 515) | (n = 415) | (n = 128) |
| 60–80 | 73.69 (4.40) | 70.60 (3.89) | 72.10 (5.05) | 70.65 (0.67) | 73.76 (3.78) |
| APOE*4+ | 72.07 (4.77) | 70.24 (3.76) | 71.34 (4.98) | 70.64 (0.68) | 73.14 (3.89) |
| APOE*4− | 74.44 (4.02) | 70.83 (3.95) | 72.40 (5.06) | 70.66 (0.67) | 74.08 (3.71) |
| Sex, n (%) | (n = 229) | (n = 2294) | (n = 515) | (n = 415) | (n = 128) |
| Female | 126 (55.0%) | 1431 (62.4%) | 278 (56.6%) | 201 (48.4%) | 71 (55.5%) |
| APOE*4+ | (n = 72) | (n = 876) | (n = 144) | in = 117) | (n = 43) |
| Female | 43 (59.7%) | 541 (61.8%) | 79 (54.9%) | 55 (47.0%) | 25 (58.1%) |
| APOE*4− | (n = 157) | (n = 1418) | (n = 371) | (n = 298) | (n = 85) |
| Female | 83 (52.9%) | 890 (62.8%) | 215 (60.0%) | 146 (49.0%) | 46 (54.1%) |
| Education (y) | (n = 229) | (n = 2292) | (n = 515) | (n = 415) | (n = 128) |
| Mean (SD) | 16.54 (2.51) | 16.62 (2.68) | – | – | 16.23 (3.00) |
| <13, n (%) | 23 (10.0%) | 202 (8.8%) | 235 (45.6%) | 170 (41.0%) | 26 (20.3%) |
| ≥13, n (%) | 206 (90.0%) | 2090 (91.1%) | 280 (54.4%) | 245 (59.0%) | 102 (79.7%) |
| MMSE score | (n = 229) | (n = 2294) | (n = 515) | (n = 415) | (n = 128) |
| Mean (SD) | 29.12 (1.07) | 28.96 (1.13) | 28.75 (1.20) | 29.28 (0.90) | 29.28 (0.87) |
| Amyloid PET, n (%) | (n = 229) | (n = 2294) | (n = 515) | (n = 415) | (n = 128) |
| Amyloid positive | 97 (42.4%) | 632 (27.6%) | 183 (35.5%) | 73 (17.6%) | 49 (38.3%) |
| APOE*4+ | (n = 72) | (n = 876) | (n = 144) | (n = 117) | (n = 43) |
| Amyloid positive | 48 (66.7%) | 426 (48.6%) | 85 (59.0%) | 42 (35.9%) | 30 (69.8%) |
| APOE*4− | (n = 157) | (n = 1418) | (n = 371) | (n = 298) | (n = 85) |
| Amyloid positive | 49 (31.2%) | 206 (14.5%) | 98 (26.4%) | 31 (10.4%) | 19 (22.4%) |
Data were available from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Anti-Amyloid Treatment in Asymptomatic Alzheimer disease Study (A4), the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL), Insight 46 (a neuroscience sub-study of the MRC National Survey of Health and Development), and the Harvard Aging Brain Study (HABS).
Key: APOE, Apolipoprotein E*4; MMSE, mini-mental state examination; PET, positron emission tomography; SD, standard deviation.
In the Insight 46 cohort, the rs7412 variant (which provides information on APOE*2 status) was not directly genotyped in all subjects and could not be imputed with high reliability.